Gilberto de lima Lopes Junior, Chief of the Division of Medical Oncology at the Sylvester Comprehensive Cancer Center, shared a post on LinkedIn:
“Trials Likely to Shape Lung Cancer Care in 2026
EGFR-Mutant NSCLC: Beyond MARIPOSA and FLAURA2
1. TROPION-Lung14 / TROPION-Lung15
Datopotamab deruxtecan–based strategies in EGFR-mutant NSCLC, including combinations with EGFR TKIs. These trials test whether ADC-based intensification can outperform established TKI-centric first-line approaches.
2. FURVENT
Firmeonertinib versus platinum-pemetrexed chemotherapy. A positive result would further validate next-generation EGFR TKIs as chemotherapy-replacing options in earlier lines.
3. Post-osimertinib combination studies (various sponsors)
Several phase III programs are evaluating rational combinations aimed at delaying or overcoming resistance, with PFS and OS readouts expected to mature in 2026.
ADC Expansion Across Molecular Subsets
4. DESTINY-Lung04
Trastuzumab deruxtecan in earlier-line HER2-mutant NSCLC. A key test of whether HER2-targeted ADCs move from salvage to frontline-adjacent settings.
5. TROPION-Lung01 / Lung05 (mature OS analyses)
Datopotamab deruxtecan across biomarker-unselected and selected NSCLC populations. These readouts will determine how broadly TROP2 ADCs can be deployed
6. MET-directed ADC and combination programs
Follow-on trials building on telisotuzumab vedotin, including combinations and earlier-line use, with efficacy and tolerability data expected to mature.”
More posts featuring Gilberto Lopes.